Pharma Archives | Consumer Edge

Phoebe Spear

Jul 16, 2026 | 5 minutes read | Insights

Brinsupri's Build to $1 Billion

Insmed shares fell ~20% after its 1Q2026 earnings call despite reporting $207.9 million in Brinsupri revenue, ahead of VA consensus of $198 million. ...

Learn More

How Consumer Edge Claims Data Forecasted 1Q2026 Pharma and MedTech Revenue

Grace Carlson

Jun 17, 2026 | 5 minutes read | Insights

Claims Data earnings Healthcare Hydrus Medical MedTech Pharma Phoenix Pharmacy Revenue Forecasting

How Consumer Edge Claims Data Forecasted 1Q2026 Pharma and MedTech Revenue

Consumer Edge's Phoenix pharmacy claims and Hydrus medical claims datasets provide visibility into utilization trends for a broad universe of therape...

Learn More

Aug 4, 2021 | 5 minutes read | Healthcare>Pharmacy

Earnest Analytics Earnest Healthcare Earnings predictions Healthcare Horizon Therapeutics Infusion Therapeutic & Medical Device Utilization Tag | Consumer Edge Leo Medical Claims Leo Pharmacy Claims Market access Medical Claims Opthalmology Patient persistence Patients counts Pharma Retail Tepezza Trends by indication

Tepezza Disrupted

More than a year after the landmark FDA approval of Horizon Therapeutics’ Tepezza (teprotumumab) to treat Thyroid Eye Disease (TED), we looked at h...

Learn More

Narcolepsy Treatment: Xywav Making Waves

Jul 15, 2021 | 5 minutes read | Healthcare>Pharmacy

Earnest Analytics Healthcare Data Jazz Pharmaceuticals Leo Medical Claims Leo Pharmacy Claims Narcolepsy Patient counts Pharma Retail and specialty drug utilization Xyrem Xywav

Narcolepsy Treatment: Xywav Making Waves

Jazz Pharmaceuticals has historically relied on its top-selling medication Xyrem, a narcolepsy medication, accounting for almost 75% of the company�...

Learn More

Tag: Pharma

Brinsupri's Build to $1 Billion

How Consumer Edge Claims Data Forecasted 1Q2026 Pharma and MedTech Revenue

Tepezza Disrupted

Narcolepsy Treatment: Xywav Making Waves

Subscribe